UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2005
SUNESIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware |
| 000-51531 |
| 94-3295878 |
(State or Other Jurisdiction |
| (Commission |
| (IRS Employer |
341 Oyster Point Boulevard |
|
|
South San Francisco, California |
| 94080 |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (650) 266-3500
Not Applicable
(Former Name or Former Address, if Changed Since Last Report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On November 14, 2005, Sunesis Pharmaceuticals, Inc. (“Sunesis”) issued a press release announcing its financial results for the quarter ended September 30, 2005. A copy of the press release is attached hereto as Exhibit 99.1.
This report contains forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements.
Item 9.01. Financial Statements and Exhibits
Press release issued by Sunesis Pharmaceuticals, Inc., dated November 14, 2005.
* * * * * * * * *
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SUNESIS PHARMACEUTICALS, INC. | ||
|
| ||
|
| ||
Date: November 14, 2005 |
| ||
| By: | /s/ERIC H. BJERKJHOLT |
|
|
| Eric H. Bjerkholt | |
|
| Senior Vice President and Chief Financial Officer | |
3
EXHIBIT INDEX
| Description | |
|
|
|
99.1 |
| Press release issued by Sunesis Pharmaceuticals, Inc., dated November 14, 2005. |
4
